Received Mar 7, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARCEL | VARICELLA (VARIVAX) | MERCK & CO. INC. | 2 | — | — |
| VARCEL | VARICELLA (VARIVAX) | MERCK & CO. INC. | UNK | Y015101 | — |
| VARCEL | VARICELLA (VARIVAX) | MERCK & CO. INC. | UNK | — | — |
| VARCEL | VARICELLA (VARIVAX) | MERCK & CO. INC. | UNK | — | — |
No additional adverse event; HCP called to report a patient received their first does of VARIVAX at 12 months of age and was administered a second dose just 3 months later at 15- months of age. Caller states no side effects or symptoms have been reported. HCP does not have the l; Information has been received from a Registered Nurse on 12-FEB-2025 regarding to an 1-year-old patient of unknown gender. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. It was reported that the patient received their first dose of Varicella Virus Vaccine Live (Oka-Merck) at 12 months of age on 03-NOV-2024 (dose, lot #and expiration date was not reported) and it was administered a second dose, reported as just 3 months later at 15- months of age on 03-FEB-2025 (dose: 0.5 milliliter, lot #Y015101, expiration date: 06-SEP-2026) (Inappropriate schedule of product administration) for prophylaxis. It was reported that no side effects or symptoms had been reported.